

Franklin Biotechnology Discovery Fund

A (acc) JPY-H1: LU2999659290

Sector | Factsheet as of 31 October 2025

This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.

Investment Overview

To seek long-term investment growth, through growth of capital. The Fund mainly invests in equities of biotechnology companies and discovery research firms of any market capitalisation. This may include companies involved with genomics, genetic engineering and gene therapy as well as companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture. These investments may be from anywhere in the world, although the Fund may invest significantly in the US.

Performance

Under current legislation, we are not allowed to display performance data with less than a complete 12 month performance record.

This share class will attempt to hedge the currency risk between the base currency of the Fund and the currency of the share class, although there can be no guarantee that it will be successful in doing so.

Fund Overview

Umbrella	Franklin Templeton Investment Funds
Fund Base Currency	USD
Fund Inception Date	03/04/2000
Share Class Inception Date	28/03/2025
Minimum Investment	USD 1000
ISIN	LU2999659290
Bloomberg	FRABDAJ LX
EU SFDR Category	Article 8

Benchmark(s) and Type

NASDAQ Biotechnology Index	Comparator
----------------------------	------------

Charges

Maximum Initial Charge	5.75%
Exit Charge	—
Ongoing Charges Figure	1.80%
Performance Fee	—

The charges are the fees the Fund charges to investors to cover the costs of running the Fund. Additional costs, including transaction fees, will also be incurred. These costs are paid out by the Fund, which will impact on the overall return of the Fund. Fund charges will be incurred in multiple currencies, meaning that payments may increase or decrease as a result of currency exchange fluctuations.

Fund Characteristics

	Fund
NAV-A (acc) JPY-H1	¥1,384.93
Total Net Assets (USD)	\$1.68 Billion
Number of Issuers	78
Average Market Cap (Millions USD)	\$51,125
Historical EPS Growth (3 Yr)	-8.65%

Top Equity Issuers (% of Total)

	Fund
GILEAD SCIENCES INC	5.62
VERTEX PHARMACEUTICALS INC	4.57
AMGEN INC	4.51
ARGENX SE	4.13
REGENERON PHARMACEUTICALS INC	4.10
JAZZ PHARMACEUTICALS PLC	4.02
ALNYLAM PHARMACEUTICALS INC	3.84
INSMED INC	3.80
PRAXIS PRECISION MEDICINES INC	3.10
ASCENDIS PHARMA A/S	2.88

Sector Allocation (% of Total)

	Fund
Biotechnology	79.76
Pharmaceuticals	13.39
Health Care Services	2.60
Life Sciences Tools & Services	1.13
Managed Health Care	0.22
Cash & Cash Equivalents	2.90

Market Cap Breakdown (% of Equity) (USD)

	Fund
<2.0 Billion	21.40
2.0-5.0 Billion	19.66
5.0-10.0 Billion	10.60
10.0-25.0 Billion	12.10
25.0-50.0 Billion	4.44
>50.0 Billion	31.34
N/A	0.47

Portfolio Management

	Years with Firm	Years of Experience
Evan McCulloch, CFA	33	33
Akiva Felt	7	18

What are the Risks?

The Fund does not offer any capital guarantee or protection and you may not get back the amount invested. The Fund is subject to the following risks which are materially relevant: **Liquidity risk:** the risk that arises when adverse market conditions affect the ability to sell assets when necessary. Such risk may be triggered by (but not limited to) unexpected events such as environmental disasters or pandemics. Reduced liquidity may have a negative impact on the price of the assets. **Equity risk:** prices of equities may be affected by factors such as economic, political, market, and issuer-specific changes. Such changes may adversely affect the value of the equities regardless of company-specific performance. **Securities Lending risk:** the risk that default or insolvency of the borrower of securities lent by a Fund may lead to losses if collateral received realises less than the values of securities lent. Complete information on the risks of investing in the Fund are set out in the Fund's prospectus.

Glossary

Ongoing Charges Figure (OCF): The Ongoing Charges Figure (OCF) includes the fees paid to the management company, the investment manager and the depository, as well as certain other expenses. The OCF is calculated by taking the relevant main material costs paid out over the 12-month period indicated and dividing them by the average net assets over the same period. The OCF does not include all expenses paid by the fund (for example, it does not include what the fund pays for buying and selling securities). For a comprehensive list of the types of costs deducted from fund assets, see the prospectus. For recent all-in annual costs, as well as hypothetical performance scenarios that show the effects that different levels of return could have on an investment in the fund, where applicable, see the KID. For funds that lack 12 months of data, or for which OCF is not likely to give a fair idea of likely future costs, the figure shown is an estimate. **Comparator:** Benchmark is used for comparing Fund performance, but is not a constraint to Fund Investment. **Weighted Average Market Capitalization:** A determination of a company's value, calculated by multiplying the total number of company stock shares outstanding by the price per share. For a portfolio, the value represents a weighted average based on the stocks held. **Historical 3 Yr EPS Growth:** A measure of the growth of earnings per share over a trailing 3 year period. For a portfolio, the value represents a weighted average of the stocks it holds.

Portfolio Data Information

Holdings are provided for information purposes only and should not be deemed a recommendation to buy or sell the securities mentioned.

Important Information

This fund meets the requirements under Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR); the fund has binding commitments in its investment policy to promote environmental and/or social characteristics and any companies in which it invests should follow good governance practices.

Further information in relation to the sustainability-related aspects of the Fund can be found at www.franklintempleton.lu/SFDR. Please review all of the Fund's objectives and characteristics before investing. This material is intended to be of general interest only and should not be construed as investment advice. It does not constitute legal or tax advice and it is not an offer for shares or an invitation to apply for shares of the Luxembourg-domiciled SICAV Franklin Templeton Investment Funds (the "Fund" or "FTIF"). For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the fund and will not be investing directly in the underlying assets of the fund.

Franklin Templeton ("FT") provides no guarantee or assurance that the Fund's investment objective will be attained. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. **Past performance does not predict future returns.** Currency fluctuations may cause the value of a Fund's investments to diminish or increase.

FT shall not be liable to any user of this document or to any other person or entity for the inaccuracy of information or any errors or omissions in its contents, regardless of the cause of such inaccuracy, error or omission. Any opinions expressed are the author's at publication date and they are subject to change without prior notice. Any research and analysis contained in this material has been procured by FT for its own purposes and is provided to you only incidentally. Data from third party sources may have been used in the preparation of this document and FT has not independently verified, validated or audited such data.

No shares of the Fund may be directly or indirectly offered or sold to residents of the United States of America. Shares of the Fund are not available for public distribution in all jurisdictions and prospective investors, who are not financial professionals, should consult their financial advisor before deciding to invest. The Fund may use financial derivatives or other instruments which may entail specific risks more fully described in the Fund's Documents.

Subscriptions to shares of the Fund should only be made on the basis of the Fund's current Prospectus, and, where available, the relevant KID, accompanied by the latest available audited annual report and the latest semi-annual report if published thereafter. These documents can be found on our website at www.franklinresources.com/all-sites, obtained, free of charge, from your local FT representative or can be requested via FT's European Facilities Service which is available at www.eifs.lu/franklintempleton. The Fund's documents are available in English, Arabic, French, German, Italian, Polish and Spanish.

In addition, a Summary of Investor Rights is available from www.franklintempleton.lu/summary-of-investor-rights. The summary is available in English.

The sub-funds of FTIF are notified for marketing in multiple EU Member States under the UCITS Directive. FTIF can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.

Franklin Templeton International Services S.à r.l. – Supervised by the Commission de Surveillance du Secteur Financier – 8A, rue Albert Borschette, L-1246 Luxembourg – Tel: +352 46 66 67-1 – Fax: +352 342080 9861.

Benchmark(s) NASDAQ Biotechnology Index. Used for performance comparison only.

The Fund is actively managed and may deviate materially from that of the benchmark(s).

Base currency US dollar (USD).

Intended retail investor Investors who understand the risks of the Fund and plan to invest for at least 5 years. The Fund may appeal to investors who are looking for long-term investment growth, are interested in a thematic exposure to global equity markets as part of a diversified portfolio, have a high risk profile and can tolerate significant short-term changes in the share price.

Product availability The Fund is available to all investors with at least basic investment knowledge, through a wide range of distribution channels, with or without the need for advice.

Performance: The share class shown has adopted a hedging strategy intended to reduce the effect of exchange rate movements between the currency of the Fund's investment strategy and the currency of the share class. The benchmark returns displayed are shown in the reference currency of the Fund's investment strategy USD, while share class returns are shown in the reference currency of share class JPY. As a result, the returns shown above reflect the effect of the hedging strategy and one can compare the returns of the Fund (net of fees) relative to its benchmark index without the impact of exchange rate movements on index returns.

CFA® and **Chartered Financial Analyst®** are trademarks owned by CFA Institute.

Indices are unmanaged, and one cannot invest directly in an index. They do not reflect any fees, expenses or sales charges. Important data provider notices and terms available at www.franklintempletondatasources.com. Source: Nasdaq OMX.

In Europe (excluding Poland & Switzerland), this financial promotion is issued by Franklin Templeton International Services S.à r.l. – Supervised by the Commission de Surveillance du Secteur Financier – 8A, rue Albert Borschette, L-1246 Luxembourg – Tel: +352-46 66 67-1 – Fax: +352 342080 9861. **In Switzerland**, issued by Franklin Templeton Switzerland Ltd, Talstrasse 41, CH-8001 Zurich. Paying agent in Switzerland is BNP Paribas Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, 8002 Zurich. **In Poland**, Templeton Asset Management (Poland) TFI S.A.; Rondo ONZ 1; 00-124 Warsaw. **In the Middle East**, provided by Franklin Templeton Investments (ME) Limited, authorized and regulated by the Dubai Financial Services Authority. Franklin Templeton Investments, The Gate, East Wing, Level 2, Dubai International Financial Centre, P.O. Box 506613, Dubai, U.A.E., Tel: +9714-4284100 Fax: +352 342080 9871. **In Canada**, this material may be distributed in Canada by Franklin Templeton Investments Corp.

© 2025 Franklin Templeton. All rights reserved.